Modine Manufacturing Company vs Novo Nordisk A/S — how do they compare? Modine Manufacturing Company trades at $245.92 (market cap $12.18B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 18.1× Modine Manufacturing Company's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals.
| MOD | NVO | |
|---|---|---|
Market Cap | $12.18B | $220.53B |
Sector | Technology | Health |
52-Week High | $306.89 | $71.70 |
52-Week Low | $93.71 | $35.29 |
Enterprise Value | $12.54B | $239.49B |
Dividend Yield | — | 3.63% |
Signals from Pluang's Aura AI — not financial advice
MOD trades at $227.88, down 0.64% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.71 exceeding expectations. Revenue reached $2.58B in 2025, though net income margin is modest at 3.82%. Recent news includes institutional buying and executive appointments, while technical support sits near $221.
Analyst consensus is bullish with a $328.80 price target, but high P/E of 101.48 suggests premium valuation. Risks include margin pressure from supply chain challenges and competitive threats in data center cooling. The stock offers growth potential if margin expansion continues, but investors face volatility from technical weakness and execution risks.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →